Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shukuan Li

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Anticancer Research|October 28, 2025
Very Rapid Eradication of a Large Squamous-Cell Carcinoma of the Head and Neck Treated With First-line Combination Chemotherapy, a Low-methionine Diet, and Oral Recombinant MethioninaseYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Cancer Research|September 18, 2004
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesZhijian Yang, Junhua Wang, Quan Lu, et al.
Anticancer Research|November 29, 2025
FDG- and MET-PET Imaging Reveal Glucose and Methionine Addiction in a Primary Endometrial Cancer and Methionine Addiction only in a Para-aortic Lymph-node Metastasis in a 58-year-old PatientYohei Asano, Toshihiko Sato, Chihiro Hozumi, et al.
Anticancer Research|November 29, 2025
Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine DietYohei Asano, Qinghong Han, Shukuan Li, et al.
Oncotarget|February 9, 2018
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse modelsKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|September 3, 2025
Eradication of Extensive Lymph-Node, Bone and Pleural Metastases of a Breast-Cancer Patient Treated With Radiation, Immunotherapy and Oral Recombinant MethioninaseYohei Asano, Toshihiko Sato, Qinghong Han, et al.
Oncotarget|March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelsKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and preventionKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Anticancer Research|October 28, 2025
Very Rapid Eradication of a Large Squamous-Cell Carcinoma of the Head and Neck Treated With First-line Combination Chemotherapy, a Low-methionine Diet, and Oral Recombinant MethioninaseYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Cancer Research|September 18, 2004
PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primatesZhijian Yang, Junhua Wang, Quan Lu, et al.
Anticancer Research|November 29, 2025
FDG- and MET-PET Imaging Reveal Glucose and Methionine Addiction in a Primary Endometrial Cancer and Methionine Addiction only in a Para-aortic Lymph-node Metastasis in a 58-year-old PatientYohei Asano, Toshihiko Sato, Chihiro Hozumi, et al.
Anticancer Research|November 29, 2025
Rapid Eradication of Extensive Spinal Metastases in a Prostate-Cancer Patient Taking Androgen-deprivation Therapy, Chemotherapy, and Oral Recombinant Methioninase on a Low-Methionine DietYohei Asano, Qinghong Han, Shukuan Li, et al.
Oncotarget|February 9, 2018
Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse modelsKei Kawaguchi, Kentaro Igarashi, Shukuan Li, et al.
Cancer Diagnosis & Prognosis|September 3, 2025
Eradication of Extensive Lymph-Node, Bone and Pleural Metastases of a Breast-Cancer Patient Treated With Radiation, Immunotherapy and Oral Recombinant MethioninaseYohei Asano, Toshihiko Sato, Qinghong Han, et al.
Oncotarget|March 16, 2018
Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse modelsKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Cell Cycle (Georgetown, Tex.)|December 1, 2017
Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and preventionKei Kawaguchi, Qinghong Han, Shukuan Li, et al.
Journal of Cellular Biochemistry|November 17, 2017
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninaseKentaro Igarashi, Shukuan Li, Qinghong Han, et al.
Pageof 6